Ladenburg Thalmann Maintains Buy on Capricor Therapeutics, Raises Price Target to $25
Portfolio Pulse from Benzinga Newsdesk
Ladenburg Thalmann analyst Aydin Huseynov has maintained a Buy rating on Capricor Therapeutics (NASDAQ:CAPR) and raised the price target from $24 to $25.
May 14, 2024 | 6:23 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ladenburg Thalmann's analyst Aydin Huseynov reaffirmed a Buy rating on Capricor Therapeutics and increased the price target to $25, indicating a positive outlook on the stock.
The upgrade in the price target by a reputable analyst suggests a strong belief in the company's future performance, potentially leading to increased investor confidence and a positive short-term price movement.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100